La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Actinium Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Actinium Pharma..

Actinium Pharma (AMEX:ATNM) Azioni, Catena delle Opzioni

ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Pre-market: Palantir guida i rialzi con un +9,6%, mentre SunPower e Chegg mostrano cali significativi. Scopri i dettagli.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

Press Releases

Life Sciences Investor Forum Agenda Announced for June 11th-12th

Life Sciences Investor Forum: Now Available for Online Viewing

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

ADIA

BPTH

CNVIF

COCH

CSLLY

IMNN

MTVA

NIKA

PYNKF

SDZNY

SPHRY

STSS

TIVC

TSXV:CNVI

TSXV:PINK

VYCO

Actinium Pharma

BioAtla

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Equillium

Evaxion

FibroGen

Kezar Life Sciences

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

RenovoRx

Serina Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

HC Wainwright & Co.

Stephens & Co.

Maxim Group

Cantor Fitzgerald

B. Riley Securities

Screenshot 2024-02-29 at 7.16.11 PM

Biotech

General

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Comments

Actinium Pharma

Actinium Pharma (ATNM) Opzioni

Actinium Pharma (AMEX:ATNM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO